当前位置: X-MOL 学术Pediatr. Allergy Immunol. Pulmonol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Adolescent Asthma Pharmacotherapy in a State of Flux.
Pediatric Allergy, Immunology, and Pulmonology ( IF 0.9 ) Pub Date : 2015-10-01 , DOI: 10.1089/ped.2015.0562
Hengameh Raissy 1 , Kathryn Blake 2
Affiliation  

Recently, the United States Food and Drug Administration (FDA) elected not to approve a once-daily inhaled corticosteroid/long-acting β2 agonist combination product in 12-17-year-old patients due to lack of sufficient data, despite approval of previous combination products with similar levels of supporting evidence. As the FDA's stance toward adolescent data is changing, the opportunity to learn about their response to asthma medication has now arisen. A review of the relevant issues pertinent to pharmacotherapy of asthma in the 12-17-year-old population is discussed in this review.

中文翻译:

助焊剂状态下的青少年哮喘药物治疗。

最近,由于缺乏足够的数据,美国食品药品监督管理局(FDA)选择不批准每日一次吸入12-17岁患者的皮质类固醇/长效β2激动剂联合产品,尽管之前的批准具有相似证据水平的组合产品。随着FDA对青少年数据的态度发生变化,现在已经出现了了解其对哮喘药物反应的机会。本文讨论了与12-17岁人群哮喘药物治疗有关的相关问题。
更新日期:2019-11-01
down
wechat
bug